Acurx Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

ISSUANCE OF EQUITY INTERESTS (Details)

ISSUANCE OF EQUITY INTERESTS (Details) - USD ($)										1 Months Ended	12 Months Ended
ISSUANCE OF EQUITY INTERESTS (Details) - USD ($)	Dec. 21, 2021	Jun. 29, 2021	Jun. 23, 2021	Oct. 16, 2020	Jul. 20, 2020	Jan. 06, 2020	Oct. 18, 2019	Aug. 08, 2019	Mar. 29, 2019	Oct. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2018	Jan. 31, 2020
Class of Warrant or Right [Line Items]
Share issued price per share									$ 2.00
Percentage of private placement offerings warrant coverage													50.00%
Units Issued During Period Shares New Issues						182,002	483,501	1,248,750	277,000
Common stock, Authorized (in shares)											200,000,000	200,000,000
Common stock, Outstanding (in shares)											10,215,792
Initial Public Offering, net of cash issuance costs (in shares)		2,875,000
Proceeds from Initial Public Offering, net of issuance costs		$ 17,300,000									$ 14,797,132
Cash issuance cost											$ 2,452,868	$ 51,409
Converted shares of common stock		7,041,208
Expected term											6 years 2 months 12 days
Risk-free interest rate											1.09%
Warrant
Class of Warrant or Right [Line Items]
Number of warrants												10,077
Exercise price		$ 2.88								$ 3.25
Expected term										10 years
Risk-free interest rate										0.32%
Exercise price										$ 3.25
Members' Equity, Class A
Class of Warrant or Right [Line Items]
Share issued price per share											$ 3.25			$ 2.50
Number of shares called by Warrant									1
Number of warrants									0.5
Units Issued During Period Shares New Issues									277,000
Proceeds From Issuance Of Private Placement									$ 554,000
Exercise price									$ 2.00
Warrant exercisable term									10 years
Converted shares of common stock			14,082,318
Warrants Converted to Purchase Common Stock		1,437,577
Members' Equity, Class A \| Maximum
Class of Warrant or Right [Line Items]
Units Issued During Period Shares New Issues									138,500
Members' Equity, Class B
Class of Warrant or Right [Line Items]
Converted shares of common stock			7,041,208
Members' Equity, Class A and Class B
Class of Warrant or Right [Line Items]
Converted shares of common stock		14,082,318
Private Placement
Class of Warrant or Right [Line Items]
Number of warrants				0	0
Private Placement \| Members' Equity, Class A
Class of Warrant or Right [Line Items]
Share issued price per share				$ 3.25	$ 3.25	$ 2.50	$ 2.00	$ 2.00
Number of shares called by Warrant						1	1	1
Number of warrants						0.25	1	1
Units Issued During Period Shares New Issues				705,727	533,900	182,002	483,501	1,248,750
Proceeds From Issuance Of Private Placement				$ 2,293,613	$ 1,735,175	$ 455,005	$ 967,000	$ 2,497,500
Exercise price						$ 2.50	$ 2.00	$ 2.00
Warrant exercisable term						10 years	10 years	10 years
Private Placement \| Members' Equity, Class A \| Maximum
Class of Warrant or Right [Line Items]
Units Issued During Period Shares New Issues						45,501	241,751	624,375
Private Placement One
Class of Warrant or Right [Line Items]
Share Price													$ 1.00
Private Placement Two
Class of Warrant or Right [Line Items]
Share Price													$ 1.50
IPO
Class of Warrant or Right [Line Items]
Share issued price per share		$ 6.00
Units Issued During Period Shares New Issues		2,875,000
Exercise price	$ 7.50
Warrant exercisable term	4 years 6 months
Proceeds from Initial Public Offering, net of issuance costs		$ 14,800,000
Cash issuance cost		$ 2,400,000
Warrants issued to Underwriter											150,000
Fair value of Warrants											$ 618,000
Expected term											4 years 6 months
Risk-free interest rate											0.79%
Exercise price											$ 6.26
volatility rate											94.00%